STOCK TITAN
  1. Home
  2. Sec-filings
  3. EPRX
  4. [6-K] Eupraxia Pharmaceuticals Inc. Current Report (Foreign Issuer)

[6-K] Eupraxia Pharmaceuticals Inc. Current Report (Foreign Issuer)

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
6-K

Filing content is currently unavailable.

Source: View Original Filing on SEC EDGAR

Stock EPRX logo
Eupraxia Pharmac

NASDAQ:EPRX

EPRX Rankings

#4233 Ranked by Market Cap
N/A Ranked by Dividends

EPRX Latest News

Sep 2, 2025
First Set of 1-Year Clinical Results from RESOLVE Trial in Eosinophilic Esophagitis (EoE), Durable and Sustained Symptom & Tissue Responses after Dosing with EP-104GI
Aug 12, 2025
Eupraxia Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update
Jul 22, 2025
Eupraxia Pharmaceuticals Invited to Present at Upcoming Investor Conferences
Jul 8, 2025
Eupraxia Doses First Patient in Phase 2b Placebo-Controlled Portion of EP-104GI RESOLVE Trial in Eosinophilic Esophagitis
Jun 2, 2025
Eupraxia Pharmaceuticals Announces Voting Results from Annual General and Special Meeting of Shareholders

EPRX Latest SEC Filings

Sep 2, 2025
[6-K] Eupraxia Pharmaceuticals Inc. Current Report (Foreign Issuer)
Jul 8, 2025
[6-K] Eupraxia Pharmaceuticals Inc. Current Report (Foreign Issuer)

EPRX Stock Data

192.74M
29.08M
19.13%
5.3%
0.49%
Biotechnology
Healthcare
Link
Canada
Victoria